Sandostatin Lar

Acromegaly, Flushing, Gastroenteritis + 4 more

Treatment

6 FDA approvals

17 Active Studies for Sandostatin Lar

Treatment for

Acromegaly

What is Sandostatin Lar

Octreotide

The Generic name of this drug

Treatment Summary

Acromegaly is a disorder caused when the body produces too much growth hormone, leading to increased growth in body tissues and metabolic problems. Octreotide is a medication that helps to reduce growth hormone levels and is used to treat acromegaly and symptoms from various tumors. The drug is usually given as an injection, but on June 26, 2020, the FDA approved the first oral form of octreotide, Mycapssa, for long-term maintenance treatment of acromegaly.

Octreotide Acetate

is the brand name

image of different drug pills on a surface

Sandostatin Lar Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Octreotide Acetate

Octreotide

1988

Approved as Treatment by the FDA

Octreotide, otherwise known as Octreotide Acetate, is approved by the FDA for 6 uses such as metastatic Carcinoid Tumors and Gastroenteritis .

metastatic Carcinoid Tumors

Gastroenteritis

Diarrhea

Carcinoid Tumor

Acromegaly

Helps manage Acromegaly

Flushing

Effectiveness

How Sandostatin Lar Affects Patients

Octreotide is a drug that works like the natural hormone somatostatin. It is used to treat issues related to tissue growth and insulin regulation in people with acromegaly. It also helps reduce flushing and diarrhea from gastrointestinal tumors. People taking octreotide should be aware that it may reduce gallbladder contractility, bile secretion and the release of thyroid-stimulating hormone (TSH). Additionally, there have been reports of decreased vitamin B12 levels in people taking octreotide, so it is important to monitor vitamin B12 levels in these patients.

How Sandostatin Lar works in the body

Octreotide is a medication that helps treat excessive growth hormones and other issues related to tumors. It works by binding to specific receptors in the body and causing muscles in blood vessels to tighten. This process then shuts off the production of growth hormones and other hormones involved in the symptoms associated with tumors, like flushing and gastrointestinal problems. Octreotide also reduces the amount of luteinizing hormone and decreases the amount of blood going to certain organs.

When to interrupt dosage

The advocated dosage of Sandostatin Lar is contingent upon the determined circumstance, including Acromegaly, Vasoactive Intestinal Peptide Tumors and metastatic Carcinoid Tumors. The degree of dosage alters, as per the method of delivery (e.g. Injection - Intravenous; Subcutaneous or Capsule, delayed release) mentioned in the following table.

Condition

Dosage

Administration

Flushing

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

Carcinoid Tumor

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

octreotide

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Acromegaly

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Gastroenteritis

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Vasoactive Intestinal Peptide Tumors

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

long-term maintenance therapy

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Warnings

Sandostatin Lar Contraindications

Condition

Risk Level

Notes

known hypersensitivity to the drug or any of the ingredients

Do Not Combine

There are 20 known major drug interactions with Sandostatin Lar.

Common Sandostatin Lar Drug Interactions

Drug Name

Risk Level

Description

Dotatate gallium Ga-68

Major

Octreotide may decrease effectiveness of Dotatate gallium Ga-68 as a diagnostic agent.

Eliglustat

Major

The metabolism of Eliglustat can be decreased when combined with Octreotide.

Fentanyl

Major

The metabolism of Fentanyl can be decreased when combined with Octreotide.

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxyzine.

Lutetium Lu 177 dotatate

Major

The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide.

Sandostatin Lar Toxicity & Overdose Risk

Very few cases of octreotide overdose have been reported, with doses ranging from 2.4 mg/day to 6 mg/day. Side effects of octreotide overdose may include low blood pressure, oxygen deprivation in the brain, irregular heartbeat, heart attack, buildup of lactic acid, pancreatic inflammation, enlarged liver, diarrhea, flushed skin, fatigue, and weakness.

image of a doctor in a lab doing drug, clinical research

Sandostatin Lar Novel Uses: Which Conditions Have a Clinical Trial Featuring Sandostatin Lar?

Currently, 41 active clinical trials are assessing the potential of Sandostatin Lar in providing long-term maintenance therapy for metastatic Carcinoid Tumors, as well as for attenuating flushing.

Condition

Clinical Trials

Trial Phases

Acromegaly

6 Actively Recruiting

Phase 2, Phase 3, Phase 1

Flushing

0 Actively Recruiting

Gastroenteritis

12 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Early Phase 1

Vasoactive Intestinal Peptide Tumors

0 Actively Recruiting

Carcinoid Tumor

1 Actively Recruiting

Early Phase 1

long-term maintenance therapy

0 Actively Recruiting

octreotide

0 Actively Recruiting

Sandostatin Lar Reviews: What are patients saying about Sandostatin Lar?

Patient Review

11/20/2013

Sandostatin Lar for Carcinoid Syndrome

I've been on Sandostatin monthly for 14 months, after being diagnosed with a NET tumor of the pancreas with metastasis to the liver last summer. I'm really pleased because there have been no side effects and my blood work shows lowered chromogranin levels - which delights my oncologist. The injection is painful but it's a small price to pay for being able to live a basically normal life at age 60.

Patient Review

1/13/2010

Sandostatin Lar for Carcinoid Syndrome

My oncologist put me on this drug in October 2009. I have been having monthly injections since, and my blood work looks much better now. My stomach cramps have also improved a lot. The only downside is that it seems like my hair isn't growing as fast, but I don't know if the two are related.

Patient Review

4/24/2020

Sandostatin Lar for Carcinoid Syndrome

I've been using this medication for over fifteen years with great success. When I started, I had five spots on my liver and now there are only three remaining. The company that makes the drug is also very supportive, checking in with me monthly to see how I'm doing.

Patient Review

12/5/2016

Sandostatin Lar for Carcinoid Syndrome

I've been taking Sandostatin for about 10 years now. It's helped me shrink a tumor to the point where it could be surgically removed, and I'm still taking it as a preventative measure.

Patient Review

10/8/2008

Sandostatin Lar for Carcinoid Syndrome

I started this treatment in November 2001 and have been using it every four weeks since. I'm up to a 40mg dose and it has really helped stabilize the tumors in my liver, according to my doctor at MD Anderson Clinic in Houston, Texas.

Patient Review

9/15/2010

Sandostatin Lar for Increased Size of Hands, Feet and Face

I have acromagly and, post-surgery, I was getting a lot of headaches. This medication completely relieved the pain and has allowed me to live a whole new life.

4.7

Patient Review

3/3/2011

Sandostatin Lar for Carcinoid Syndrome

The Sandostatin LAR injections at 30mg have helped to normalize my bowel movements and reduced the frequency of flushing episodes.

4.3

Patient Review

12/8/2009

Sandostatin Lar for Pancreatic Tumor causing Excessive Secretion of Insulin

Sandostatin LAR has been highly effective in managing my insulinoma.

4.3

Patient Review

11/23/2009

Sandostatin Lar for Carcinoid Syndrome

Since I started getting this treatment every 4 weeks, it's been great. The first month didn't show much of a difference, but now my symptoms only come up occasionally. However, in the last 3-4 weeks, I've experienced sore muscles and unexplained weight loss. I haven't changed my diet or exercise habits, but lost 3# in one week and a total of 5# in the last month. I'll be discussing this with my oncologist soon to see what he thinks. Other than that, the drug has helped me lead a more normal life.

3.7

Patient Review

5/26/2009

Sandostatin Lar for Carcinoid Syndrome

This treatment helped me for a while, but now I'm dealing with some serious side effects. My blood sugar is high, my blood pressure is out of control, and I have muscle pain all over my body. If someone so much as touches me, it hurts. I've been told this could be a side effect of the treatment, but I'm really not sure.

3.3

Patient Review

1/4/2013

Sandostatin Lar for Carcinoid Syndrome

I receive an IM injection of 30 mg every four weeks. However, this has not been effective in slowing the growth of carcinoid tumors on my liver after two years. I've had to have SIRT procedures done to remove the tumors from my liver. My oncologist says I should continue taking the injections, though.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sandostatin lar

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Sandostatin LAR?

"The most common symptoms of the flu are:

back pain
fatigue
headache
abdominal pain
nausea
dizziness"

Answered by AI

What is Sandostatin LAR used for?

"This action medication is a slow-acting form of octreotide. Octreotide is used to treat patients with serious diarrhea that is watery, and also sudden reddening in the face and neck area. These types of tumors are found mostly in the intestines and pancreas."

Answered by AI

Is Sandostatin LAR chemotherapy?

"Sandostatin is not a chemotherapy drug. Rather, it is a man-made hormone with similar effects to somatostatin, a hormone that is produced naturally in our bodies by the hypothalamus and other tissues such as the pancreas and the gastrointestinal tract."

Answered by AI

How is Sandostatin LAR given?

"Sandostatin LAR is a long-acting version of the drug octreotide, which is used to treat hormone imbalances. Octreotide is similar to the hormone somatostatin, and is more potent than somatostatin in its ability to inhibit growth hormone, glucagon, and insulin."

Answered by AI